
ONC-392
Novel antibodies selectively abrogate immune evasion in tumor microenvironment but preserve immune checkpoint against adverse events.
Loading color scheme
From novel biology to clinical stage products.
Best-in-class and first-in-class immunotherapy products targeting cancer evasion of adaptive and innate immunity.
Our team brings success from biotech pharma, and academia to OncoC4.
Novel antibodies selectively abrogate immune evasion in tumor microenvironment but preserve immune checkpoint against adverse events.
Targeting cancer cells through chimeric antigen receptors T cells (ONC-782), bi-specific antibodies (ONC-783) and antibody-drug conjugates (ONC-784).
OncoC4 has a pipeline of best-in-class and first-in-class immunotherapy products that are moving through preclinical testing.
Developing unique drugs that uncouple therapeutic effects and immunotherapy-related adverse effects.
Scientific discoveries drive explosive immunotherapy.
BioNTech to receive exclusive worldwide license from OncoC4 to develop and commercialize its anti-CTLA-4 monoclonal antibody candidate, ONC-392 BioNTech and OncoC4 will co-develop ONC-392 as monotherapy or in combination with anti-PD1 in various solid tumor indications, with a randomized Phase 3 trial planned to start in 2023 BioNTech also plans…
The Phase 2 multicenter, open-label combination trial builds upon the promising results of monotherapeutic activity of ONC-392 seen in previous clinical trial DEC 30, 2022, Rockville, Maryland -- OncoC4, Inc., a clinical-stage biopharma company developing novel immunotherapies for cancer, today announced that the first patient has been dosed in the…
30% ORR and 90% DCR in evaluable patients were achieved in the dose escalation portion of the study in metastatic cancer patients Initial results from dose-expansion show 5 partial responses (PR) and 1 disease stabilization (SD) in 6 evaluable metastatic melanoma patients Nov 07, 2022, Rockville, Maryland -- OncoC4, Inc.,…